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Abstract 
Background.  Although paclitaxel is used for hormone-resistant prostate cancer, relapse 
definitely occurs later.  Details of the molecular mechanism responsible for 
paclitaxel-resistance remain unclear.   
Methods.  We established paclitaxel-resistant cells, DU145-TxR and PC-3-TxR from 
parent DU145 and PC-3.  To characterize these cells, we examined cross-resistance to 
other anticancer drugs.  Expression of several potential genes that had been related to 
drug-resistance was compared with parent cells by RT-PCR and western blotting.  
Methylation analysis of MDR1 promoter was carried out using bisulfite-modified DNA 
from cell lines.  Knock-down experiments using siRNA were also performed to confirm 
responsibility of drug-resistance.  Finally, cDNA microarray was performed to quantify 
gene expression in PC-3 and PC-3-TxR cells. 
Results.  The IC50 for paclitaxel in DU145-TxR and PC-3-TxR was 34.0 and 43.4-fold 
higher than that in both parent cells, respectively.  Both cells showed cross-resistance to 
some drugs, but not to VP-16 and cisplatin.  Methylation analysis revealed that 
methylated CpG sites of MDR1 promoter in DU145 and PC-3 cells were demethylated in 
DU145-TxR cells, but not in PC-3-TxR cells.  Knock down of P-gp, which was 
up-regulated in resistant cells, by MDR-1 siRNA restored paclitaxel sensitivity in 
DU145-TxR but not in PC-3-TxR, indicating that up-regulation of P-gp was not always 
main cause of paclitaxel-resistance.  Microarray analysis identified 201 (1.34%) 
up-regulated genes and 218 (1.45%) out of screened genes in PC-3-TxR. 
Conclusions.  Our data will provide molecular mechanisms of paclitaxel-resistance and 
be useful for screening target genes to diagnose paclitaxel sensitivity. 
 Introduction 
 Prostate cancer (PCa) is the most common malignancy and the second most 
frequent cause of cancer-related death of men in the United States (1).  Androgen 
deprivation treatment is very effective for more than 80% of advanced prostate cancer.  
More than half of those cases of advanced prostate cancer become resistant to deprivation 
treatment after several years and then several other palliative treatments, such as 
estramustine phosphate (EMP), steroids, are employed for these patients.  However, the 
results are very disappointing because a half of those cases lead to death within a year or 
two years. 
 Recently, the taxanes (paclitaxel or docetaxel) with other agents, such as EMP 
or predonisone have been used for hormone-resistant prostate cancer (HRPC) and have 
shown good response (2-5).  Paclitaxel, which is purified from Taxus brevifolia, 
stabilize microtubule and causes apoptosis (6).  The response rates of taxane-based 
combination therapies are better than combination therapies with other anti-cancer agents.  
However, even HRPC treated with paclitaxel-based chemotherapy also relapses as 
occurred using other anti-cancer agents.  Then the prognosis of the patients after the 
relapse is extremely poor. 
 In order to investigate the mechanisms of paclitaxel-resistance, several 
paclitaxel-resistance cell lines have been generated in ovarian cancer, breast cancer, and 
lung cancer (7,8).  Some of major mechanisms of taxane-resistance are overexpression of 
multiple drug resistance (MDR1), and multidrug resistance protein (MRP) family (9).  
Especially accumulation of P-glycoprotein encoded from MDR1 might cause resistance 
of several drugs in some cancers.  The microtubule dynamics may also be important for 
paclitaxel-resistance because the target of paclitaxel is the microtubule (10).  As for the 
role of bcl-2 as a modulator of paclitaxel sensitivity remains controversial.  In 
human paclitaxel-resistant hepatocellular carcinoma cells bcl-2 was overexpressed (11).  
Whereas bcl-2 expression was consistently down-regulated in T47-D breast cancer cells 
(12).  In prostate cancer, although Bcl-2/Bcl-xL bispecific antisense oligonucleotide also 
enhanced paclitaxel chemosensitivity in PC-3 and LNCaP cells (13,14), involvement to 
paclitaxel-resistance of Bcl-2/Bcl-xL in prostate cancer is not clear.  Recently cDNA 
microarray analyses were performed in order to reveal the key genes that are related with 
paclitaxel resistance.  Not only MDR-1 gene but also Rho guanine dinucleotide 
phosphate dissociation inhibitor beta (RhoGDI) and insulin-like growth factor binding 
protein 3 (IGFBP-3) were up-regulated in paclitaxel-resistant ovarian cancer cell lines 
(15).  Villeneuve described that 1.9% of 1728 genes were regulated in paclitaxel-resistant 
MCF-7 breast cancer cells (16).  Thus it is very important to know the mechanisms of 
paclitaxel-resistance in prostate cancer. 
 In the present study, we established two paclitaxel-resistant cell lines from 
androgen-independent DU145 and PC-3 prostate cancer cell lines by increasing 
concentration of paclitaxel gradually.  Although both cell lines showed resistance to 
paclitaxel over 30 times more than parents cells and cross-resistance to other anticancer 
drugs, the mechanism of resistance was different. 
 
Materials and Methods 
Cell Culture and Cell Proliferation Assay. 
DU145 and PC-3 cells purchased from American type culture collection were cultured in 
Dulbecco's modified Eagle medium (DMEM) and RPMI1640 containing 5% fetal calf 
serum (FCS) and penicillin/streptomycin (Invitrogen, CA, USA).  Cell growth inhibition 
assay was preformed by plating 1 x 105 cells on 6-well plates.  Twenty-four h later, cells 
were treated with the indicated concentration of anticancer agents, and cultured for an 
additional 48 h.  At the end of the culture period, the cells were trypsinized and counted 
with a hemocytometer. 
 
Establishment of paclitaxel-resistant DU145 and PC-3 cell lines 
Paclitaxel-resistant cancer cells were obtained by stepwise increased concentrations of 
paclitaxel.  DU145 and PC-3 cells maintained as described above were incubated with 10 
nM paclitaxel for 2 days.  Then the medium was changed to fresh one without paclitaxel 
and cells were cultured cells grow well.  Whenever we subcultured, the cells were 
incubated with gradual increasing concentration of paclitaxel for 2 days and cultured 
without paclitaxel until cells grow well.  Some aliquots of the cells were stored whenever 
we subcultured it.  When cells were killed by increased paclitaxel, the aliquot were 
subcultured again and lower concentration of paclitaxel was used for treatment.  Cells 
that grew at the maximum concentration of paclitaxel were stored for further analyses.  
For maintenance of paclitaxel-resistant cells, 10 nM paclitaxel was added into the normal 
medium every time. 
 
RNA Extraction and RT-PCR.  Twenty-four h after plating of 1 x 106 DU145 or PC-3 
cells, total RNA was purified with RNeasy mini kit (QIAGEN, Maryland, USA).  
Complementary DNA (cDNA) was made by reverse-transcription (RT) of 1 µg each total 
RNA using ThermoScript RT-PCR system (Invitrogen).  Each cDNA sample was 
amplified with ExTaq (TAKARA, Japan).  PCR reactions for indicated genes were 
carried out using the following forward (F) and reverse (R) in Table 1.  Each of the 
amplified PCR products was determined by electrophoresis on an 1.5% agarose gel. 
 
Western blot analysis.  Twenty-four h after plating 1 x 106 DU145, DU145-TxR, or 
PC-3, and PC-3-TxR cells on 6 cm dishes in DMEM-5% FBS, the cells were lysed with 
200 μl hypotonic buffer (20 mM Tris-HCl (pH 7.6), 10 mM NaCl, 1 mM MgCl2, and 
0.5% NP-40) and the membrane and cytosol fraction were collected by centrifugation as 
described previously (17).  To extract nuclear protein, the centrifuged pellet after 
separating cytosol fraction was lysed with 50 μl hypertonic buffer (20 mM Tris-HCl (pH 
7.6), 0.42 M NaCl, 1 mM EDTA, and 0.5% NP-40) and nuclear fraction were collected 
by centrifugation.  To extract whole cell protein, cells were lysed with hypertonic buffer 
directly.  Fifty μg of cytosol protein, 50 μg of whole cell protein, or 10 μg of nuclear 
protein was loaded in each lane of 7.5% or 12.5% Ready Gel J (Bio-Rad, NY), subjected 
to electrophoresis, then electrotransferred to a PVDF-membrane (Bio-Rad).  The 
immobilized proteins were incubated with primary antibody, P-gp (rabbit polyclonal IgG, 
200-fold dilution) (Santa Cruz, CA), YB-1 (goat polyclonal IgG, 200-fold dilution) 
(Santa Cruz), or GAPDH (rabbit polyclonal IgG, 1,000-fold dilution) (TREVIGEN, MD).  
The presence of primary antibody was visualized by Super signal west pico 
luminol/enhancer solution (PEARCE, IL). 
 
Methylation analysis of MDR1 promoter.  Genomic DNA from PC-3, PC-3-TxR, 
DU145, and DU145-TxR was purified using Blood & cell culture DNA mini kit 
(QUIAGEN) 24 h after 5x105 cells were plated on 6 cm dish.  One μg of DNA was 
subjected to sodium bisulfite modification kit (BisulFast DNA Modification Kit, 
TOYOBO, Osaka Japan).  223 bp MDR-1 promoter region (-183 to +40 of transcription 
initiation site) was amplified from bisulfite-modified DNA as described by Enokida H et 
al. (18,19).   The amplified DNA was further amplified using methylation-specific 
primer (MSP) or unmethylation-specific primer (USP) after 100-fold dilution of the 
amplified DNA (19). PCR reaction was modified to 94 C 15 s, 70 C 30 s, 72 C and 20 
cycles for MSP primers and 94 C 15 s, 68 C 30 s, 72 C and 20 cycles for USP primers.  
Then DNA sequence analysis was also carried out using the amplified 223 bp PCR 
products. 
 
Small interfering RNA transfection.  MDR-1 small interfering RNA (siRNA), 
LaminA/C siRNA, Non-Targeting siRNA were purchased from DHARMACON 
(Lafayette, CO).  After 3 x 104 DU145-TxR and PC-3-TxR cells or 3 x 105 those cells 
were cultured on 24-well plates or in 6-well plates for total RNA purification or for 
protein extraction, respectively, cells were transfected with 0, 10, 20, or 30 nM MDR-1 
siRNA, 30 nM LaminA/C siRNA, and 30 nM Non-Targeting siRNA by X-treme GENE 
siRNA Transfection Reagent (Roche).  Forty-eight h after transfection, total RNA and 
protein was extracted.  In order to see the effect of siRNA on drug resistance, cells were 
transfected with 30 nM MDR-1 siRNA or Non-Targeting siRNA 24 h after plating on 
24-well plates. Twenty-four later cells were treated with 0, 1, 3, 10, 30, 100, 300, and 
1000 nM paclitaxel and cultured for 48 h.  Then the cells were trypsinized and counted 
with a hemocytometer. 
 
cDNA microarray analysis 
Twenty-four h after plating of 5 x 105 PC-3 cells, Total RNA was purified with RNeasy 
mini kit (QIAGEN, Maryland, USA).  RNA samples were sent to Hokkaido system 





Establishment of paclitaxel-resistant cell lines 
 When we examined the sensitivity for paclitaxel of parent DU145 and PC-3 
cells, IC50 values of these cells were 11.3 nM and 5.0 nM, respectively (Table 2).  We 
established paclitaxel-resistant DU145 (DU145-TxR) and PC-3 (PC-3-TxR) cells by 
stepwise exposure method (from 10 nM paclitaxel) for 9 months and 15 months, 
respectively.  Cell growth inhibition assay demonstrated that these DU145-TxR and 
PC-3-TxR cells become 34.0-fold (IC50: 384.2 nM) and 43.4-fold (IC50: 217.1 nM) more 
paclitaxel-resistant than parent cells (Table 2 and Fig. 1).  We also compared the 
cross-resistance to other anticancer drugs (estramustine phosphate, vinblastin, 
doxorubicin, docetaxel, VP-16, and cisplatin) between parent and paclitaxel-resistant 
cells (Fig. 2 and 3, Table 2 and 3).  Both of DU145-TxR and PC-3-TxR cells showed 
almost same cross-resistance to estramustine phosphate, vinblastin, doxorubicin, and 
docetaxel.  However, cross-resistance to cisplatin and VP-16 was hardly observed. 
 Expression of several potential chemoresistant genes 
 Cellular mechanisms of drug resistance include in decreasing intracellular drug 
concentrations by increased efflux or decreased influx.  The drug distribution in an 
organism is highly dependent on transporters which play a role in absorption and 
elimination.  P-glycoprotein (P-gp) and multidrug resistance associated protein (MRP) 
which belong to the ABC (ATP-binding cassettes) family are well-known typical 
transporters.  We evaluated the expression of MDR-1 and MRP1 to MRP7 of 
DU145-TxR and PC-3-TxR cells by RT-PCR.  Only MDR-1 mRNA was overexpressed 
in both cells (Fig. 4A).  Since MDR-1 mRNA was overexpressed in both cells, we 
confirmed the expression of P-gp which was encoded from MDR-1 mRNA.  P-gp as well 
as MDR-1 mRNA was overexpressed in DU145-TxR and PC-3-TxR cells but not in 
parent cells (Fig. 4B).  Moreover, the level of P-gp in DU145-TxR cells was more 
expressed than PC-3 cells.  Since the cell death by paclitaxel is associated with apoptosis, 
we also compared the expression of major apoptosis-related genes, Bcl-2, Bax, Fas, and 
Capase-8 in these cells.  However, expression level of all of these genes was not changed 
between parent and resistant cells. 
 
Mechanisms of MDR1 overexpresssion in DU145-TxR and PC-3-TxR cells 
One of mechanisms by which of MDR-1 is overexpressed in 
paclitaxel-resistant cells is the induction by Y-box binding protein 1 (YB-1).  YB-1 is 
mainly located in the cytoplasm (20).  Once cells are exposed to UV irradiation and 
anticancer drugs, such as paclitaxel, YB-1 tanslocates into nucleus, bind to a cis-acting 
element of the MDR-1 promoter, and induce MDR-1 mRNA expression (21).  In order to 
see the nuclear localization of YB-1 protein, we performed western blot analysis.  The 
YB-1 protein level in nucleus was about 3 times higher in DU145-TxR cells than in 
DU145 cells and it was almost at the same level between PC-3 and PC-3-TxR cells (Fig. 
5A).  Nuclear localization of YB-1 was less dramatic compared to the MDR-1 expression 
in paclitaxel-resistant cells. 
Next we investigated methylation status of CpG sites at the MDR1 promoter 
region because some groups reported inverse correlation between methylation and 
MDR1 expression in (19,22,23).  Since DU145-TxR and PC-3-TxR cells 
overexpressed MDR1 mRNA compared to parent cells, we expected that 
paclitaxel-resistance might cause demethylation of CpG sites at MDR1 promoter.  
Although, methylation-specific primers (MSP) published by Enokida et al. detected 
PCR products from bisulfite-modified DNA in both parent cells and paclitaxel-resistant 
cells, unmethylation-specific primers (USP) detected stronger PCR band in DU145-TxR 
cells than in DU145 cells, suggesting that MDR1 promoter in DU145-TxR cells is less 
methylated than in DU145 cells.  However, USP did not detect PCR band in PC-3-TxR 
cells compared to PC-3 (Fig. 5B).  To further confirm the methylated CpG site at the 
MDR1 promoter, we performed DNA sequence analysis using bisulfite-modified DNA.  
The MDR1 promoter region of DU145 cells was methylated at the CpG sites of -134, 
-105, -59, -56, -51, -34, and -29 of the transcription initiation site.  The MDR1 promoter 
region of DU145-TxR cells was methylated only at the CpG site of -105 (data not sown).  
Especially, the important region for MDR1 transcriptional regulation that included a 
G-box (-59, -56, and -51)  (24) was demethylated in DU145-TxR cells (Fig. 5C).  This 
demethylation of MDR1 promoter in DU145-TxR cells was coincident with the enhanced 
MDR1 expression.  Whereas DNA sequence analysis of the amplified PCR product 
showed that the MDR1 promoter regions of PC-3 and PC-3-TxR cells were methylated at 
the CpG sites of -134, -110, -59, -51, -34, and -29 and at the CpG sites of, -110, -105, -59, 
-56, -51, and -29, respectively.  Much difference was not observed in the methylated sites 
and the number between PC-3 and PC-3-TxR promoter region.  
 
Recovery of paclitaxel sensitivity by MDR-1 knockdown 
 In order to investigate if MDR-1 mRNA overexpression in TxR cells is the 
main cause of paclitaxel resistance, we knocked-down the MDR-1 mRNA by MDR-1 
siRNA.  Ten to 30 nM MDR-1 siRNA down-regulated MDR-1 mRNA in DU145-TxR 
and PC-3-TxR cells 48 h after transfection (Fig. 5A and C).  Non-targeting siRNA and 
laminin siRNA failed to inhibit MDR-1 mRNA expression.  MDR-1 mRNA 
down-regulation by MDR-1 siRNA treatment also inhibited the expression of P-gp 
protein 
 Since MDR-1 siRNA down-regulated P-gp, we confirmed if MDR-1 
down-regulation could restore paclitaxel sensitivity.  As shown in Table 4 and Fig. 5B 
and 5D, IC50 of in parent DU145 and PC-3 cells was not changed when non-target (NT) 
siRNA or MDR-1 siRNA was transfected.  Transfection with MDR-1 siRNA into 
DU145-TxR cells after 48 h restored paclitaxel sensitivity compared to transfection with 
NT siRNA (Fig. 5B).  IC50 of paclitaxel of DU145-TxR was reduced from 537.9 nM to 
60.8 nM and recovery ratio became 88.7% 48 h after transfection (Table 4).  Whereas 
transfection with MDR-1 siRNA into PC-3-TxR cells hardly changed paclitaxel 
sensitivity.  IC50 of paclitaxel of PC-3-TxR was reduced only from 198.4 nM to 140.6 nM 
and recovery ratio became 29.1%. 
 
Mechanisms of paclitaxel resistance in PC-3-TxR cells 
Although P-gp overexpression played important role on paclitaxel resistance in 
DU145-TxR cells, this was not an important factor in PC-3-TxR cells.  There should be 
P-gp-independent pathway to become paclitaxel-resistance.  In order to identify the genes 
that are associated with on paclitaxel resistance in PC-3-TxR cells, we performed cDNA 
microarray using mRNA from parent PC-3 and PC-3-TxR cells and compared 
differentially expressed genes as described in Materials and Methods.  Approximately 
15,000 genes were screened by microarray analysis.  201 (1.34%) of screened genes were 
induced more than 2-fold and 218 (1.45%) of genes were reduced more than 2-fold in 
PC-3-TxR cell line compared with parent PC-3 cell line.  Table 5 and 6 describe the major 
30 genes that showed up-regulated and down-regulated expression in PC-3-TxR cells 
compared with PC-3 cells.  As we confirmed in Fig. 4, MDR-1 genes was up-regulated to 
6.0-fold in PC-3-TxR cells.  Some microtubule-related genes, tubuline ß6, ß2, and ß4, 
were up-regulated to 3.5-fold, 2.2-fold, and 2.1-fold in PC-3-TxR cells, respectively.  
Calcium is an important factor that is associated with microtubule polymerization.  
Calcium-binding protein, S100A9 and S100A8 were down-regulated to 4.34-fold and 
2.56-fold in PC-3-TxR cells, respectively.  Other calcium-related genes, 
tumor-associated calcium signal transducer 1 (TACSTD1), S100P, and S100A2 mRNA 
were also down-regulated in PC-3-TxR cells.  MMP-1 that is related with cancer invasion 
is overexpressed in multiple drug resistant cell lines (25).  We also observed 
overexpression of MMP-1 in PC-3-TxR cells (4.77-fold). 
 
Discussions 
In order to elucidate the mechanisms of paclitaxel-resistant in hormone 
refractory prostate cancer, we established two paclitaxel-resistant cell lines from 
androgen-independent cell lines.  Several potential mechanisms have been proposed for 
resistance to taxans.  The result that cross-resistance to cisplatin and VP-16 was not 
observed in both paclitaxel-resistant cell lines indicates that resistance to paclitaxel is 
resulted from different pathways from resistance to cisplatin and VP-16.  Although 
paclitaxel induces apoptosis, we could not detect differences of expression in 
apoptosis-related genes, such as bcl-2, bax, caspase 8 between parent cells and TxR cells.  
One of major mechanisms of paclitaxel-resistance is overexpression of P-gp (9).  The 
MDR-1 overexpression was the important factor as a responsible gene when DU145 cells 
became paclitaxel resistance.  Since MDR-1 siRNA almost restored paclitaxel sensitivity 
in DU145-TxR cells, P-gp overexpression is the main reason of paclitaxel resistance in 
this cell line. 
Our results showed that one of main mechanisms by which of MDR-1 was 
overexpressed in paclitaxel-resistant DU145 cells was the demethylation of CpG sites at 
the MDR1 promoter region.  Originally CpG sites at the MDR1 promoter region in parent 
DU145 cells were hypermethylated (19).  Because it is rare, as for the necessity of 
MDR1, expression of MDR1 is inhibited for cancer cell by methylation of MDR1 
promoter.  However, when cells can leave damage by paclitaxel, demethylation of MDR1 
promoter, especially G-box that includes Sp1-binding site and EGR-1-binding site and is 
very important for transcription (24), is promoted and induces expression of MDR1 so 
that cell themselves survives it, then cells may be going to remove paclitaxel from 
intracellular.  However, it remains unclear why PC-3-TxR cells overexpressed MDR1 
mRNA compared to PC-3 cells although the expression level in PC-3-TxR cells was 
lower than in DU145-TxR cells.  It will be very interesting to study why paclitaxel 
exposure causes demethylation of the MDR1 promoter region of DU145 cells. 
Inhibition of MDR-1 hardly restored resistance in PC-3-TxR although 
PC-3-TxR cells overexpressed P-gp compared to parent PC-3 cells.  Only by 
overexpression of p-gp, there is not explanation of the mechanism that PC -3 cells 
become paclitaxel resistance.  Other mechanisms should be involved in 
paclitaxel-resistance in PC-3-TxR cells.  Lin et al. demonstrated that doxorubicin 
resistance rat prostate cancer cell line expressed more Id-1, MIF, and GSTpi mRNA than 
parent cell line (26). They also showed that overexpression of Id-1 caused 
paclitaxel-resistance in the cell line.  However, we could not detect the difference of Id-1 
expression between PC-3 and PC-3-TxR cells although Id-1 mRNA was temporally 
down-regulated by paclitaxel treatment in PC-3 cells. 
In order to investigate what genes are involved in paclitaxel resistance, we 
compared gene expression profile between PC-3 and PC-3-TxR cells.  To our knowledge, 
this is the first report that compared gene expression profile about paclitaxel-resistance in 
hormone refractory prostate cancer cell line.  Expressions of many genes were also 
altered in paclitaxel-resistant breast cancer cells (16).  Expression patterns were similar in 
some of these genes, such as MDR1 and S100P.  However, those in PC-3-TxR cells were 
different from breast cancer cells, suggesting that different mechanisms are involved in 
becoming paclitaxel-resistance in different cancers.  
Paclitaxel shows the effect as an anticancer drug by stabilizing polymer of 
microtubule (27).  Alterations of microtubule formation in resistant cells is also important 
factors. (10,28).  Li et al. demonstrated by microarray analysis that taxotere regulated 
many genes including microtubule, apoptosis, and cell cycle-related genes in prostate 
cancer cell lines, PC-3 and LNCaP cells (29).  Especially, microtubule-related genes are 
down-regulated in those cells.  They treated cells with taxotere transiently and compare 
the regulated genes before and after treatment.  Down-regulated genes after treatment 
may be the genes which, as a result of having been impaired, were inhibited by taxotere.  
Or up-regulated genes may be the genes which, as a result, are elevated when apoptosis 
by taxotere is induced.  Ranganathan et al. demonstrated that increase in tubulin βIII 
(9-fold) and βIVa (5-fold) were observed in DU145 cells that became 
paclitaxel-resistance (30).  Orr et al. also reviewed that alterations in tubulin composition 
expression were associated with paclitaxel resistance (10).  We also confirmed the 
up-regulation of some tubulin β-6 (3.53-fold), -2 (2.22-fold), and -4 (2.13-fold) in 
PC-3-TxR cells by cDNA microarray analysis.  However, overexpression of βIII isotype 
in human prostate carcinoma cells by stable transfection failed to confer antimicrotubule 
drug resistance to these cells (31).  Interestingly, overexpression of tubulin β are related 
with poor prognosis and resistance (32).  At least overexpression of tubulin βs may be 
thought with a good marker predicting with reactivity for paclitaxel and prognosis.  We 
will investigate if overexpression of tubulin βs causes paclitaxel resistance and 
progression in PC-3 cells. 
Paclitaxel is known to repress influx of calcium into cytoplasm (33,34).  
Reduction of calcium-associated proteins expression may be a cause of repression of 
calcium influx by paclitaxel and may not be a mechanism of paclitaxel resistance.  
However, calcium dynamics which is associated with microtubule polymerization is 
important factor for paclitaxel-resistance.  Moreover, altered intracellular calcium 
homeostasis may contribute to the paclitaxel-resistant phenotype (35).  Microarray 
analysis in this study revealed a decline of S100A8/S100A9 expression in PC-3-TxR 
cells compared with parent PC-3 cells.  Calcium-induced complexes of S100A8 and 
S100A9 have been shown to colocalize with microtubules during activation of monocytes.  
They directly bind to tubulin and promote tubulin polymerization in a calcium-dependent 
manner (36).  Then failure of tetramer formation was associated with a lack of functional 
activity of S100A8/S100A9 complexes in promoting the formation of microtubules (37).  
A decline of S100A8/S100A9 expression would also inhibit the formation of 
microtubules.  Therefore, since paclitaxel cannot stabilize the formation of microtubules 
due to a decline of S100A8/S100A9 expression in PC-3-TxR cells, paclitaxel might not 
be able to show effect as an anticancer drug in resistant cells. 
In conclusions, after we established paclitaxel resistant hormone refractory 
prostate cancer cell lines, we compared resistant cells with parent cells.  This comparison 
will make it more possible to identify the genes which cause paclitaxel resistance except 
MDR-1.  Not only MDR-1 gene but also many genes were up-regulated and 
down-regulated.  We have to still distinguish the genes that are responsible for resistance 
from the genes that are regulated as a result one by one.  Nevertheless, identification of 
these genes will be useful for thinking strategies using taxanes to individual hormone 
refractory prostate cancer. 
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Table 1 The Primers used for RT- PCR analysis. 
Table 2 IC50 value of DU145 and DU145-TxR cells 
Table 3 IC50 value of PC-3 and PC-3-TxR cells 
Table 4 IC50 value of paclitaxel in iMDR-1-transfected TxR cells 
Table 5 List of genes which were overexpressed in PC-3-TxR cells 
Table 6 List of genes which were repressed in PC-3-TxR 
 
Fig. 1 Establishment of paclitaxel-treated cell lines.  DU145 (A), paclitaxel-resistant 
DU145-TxR (B), PC-3 (C), and paclitaxel-resistant PC-3-TxR (D) cells were exposed 
with indicated concentrations of paclitaxel for 24 h and counted 2 days after exposure. 
 
Fig. 2 Cross-resistance of DU145 and DU145-TxR cells.  DU145 and DU145-TxR cells 
were exposed with indicated concentrations of estramustine phosphate (EMP), docetaxel 
(DTX), vinblastin (VBL), doxorubicin (DOX), cisplatin (CDDP), and etoposide (VP-16) 
for 24 h and counted 2 days after exposure. 
 
Fig. 3 Cross-resistance of PC-3and PC-3-TxR cells.  PC-3 and PC-3-TxR cells were 
exposed with indicated concentrations of estramustine phosphate (EMP), docetaxel 
(DTX), vinblastin (VBL), doxorubicin (DOX), cisplatin (CDDP), and etoposide (VP-16) 
for 24 h and counted 2 days after exposure. 
 
Fig. 4 Expression of various drug-resistance-related genes in parent and 
paclitaxel-resistant cells.  A. RT-PCR of MDR and MRP1-7 mRNA in DU145, 
DU145-TxR, PC-3, and PC-3-TxR cells.  After mRNA was purified from these cells, 
RT-PCR was performed using primers as described in Table 1.  B. Expression of 
P-glycoprotein.  Cells were cultured for 12 h in the presence of indicated concentration of 
DHT or Adiol and harvested.  Membrane and cytosol protein were extracted as described 
in Materials and Methods and loaded on an 7.5% SDS-polyacrylamide gel for western 
blot analysis.  After protein was transferred to PVDF-membrane, anti-P-gp antibody and 
anti-GAPDH antibody were employed for detection of 170 kDa P-gp and 37 kDa 
GAPDH protein, respectively.  C. RT-PCR of bcl-2, Bax, Fas, and capase-8 mRNA in 
DU145, DU145-TxR, PC-3, and PC-3-TxR cells. 
 
Fig.  5 Expression of YB-1 protein and methylation status of MDR1 promoter 
A. Western blotting of YB-1 protein. Whole cell protein and nuclear protein were 
extracted as described in Materials and Methods and loaded on a 12.5% 
SDS-polyacrylamide gel for western blotting.  After protein was transferred to 
PVDF-membrane, anti-YB-1 or GAPDH antibody was employed for detection of 35.4 
kDa or 37 kDa YB-1 or GAPDH protein, respectively.  B. Detection of methylated and 
unmethylated promoter of MDR1 genes.  USP and MSP were employed for detection of 
unmethylated and methylated MDR1 promoter after the 223 bp MDR1 promoter region 
was amplified from bisulfite-modified DNA.  C. Bisulfite-modified DNA sequence of 
MDR1 promoter.  The sequences of bisulfite-modified MDR1 promoter regions from 
DU145, DU145-TxR, PC-3, and PC-3-TxR cells were shown from -65 to -21 of 
transcription initiation site.  Underlines and double underline show methylated CpG sites 
and G-box, respectively. 
 
Fig. 6  Paclitaxel sensitivity in iMDR-1 transfected TxR cells.  A and C. Forty-eight h 
after transfection with 0, 10, 20, or 30 nM MDR-1 siRNA, 30 nM LaminA/C siRNA (La), 
and 30 nM Non-Targeting siRNA (La), total RNA and protein was extracted according to 
the Materials and Methods.  B and D. In order to see the effect of siRNA on drug 
resistance, cells were transfected with 30 nM MDR-1 siRNA or Non-Targeting siRNA 24 
h after plating on 24-well plates. Twenty-four after transfection with 30 nM non-targeting 
iRNA or iMDR-1, cells were treated with 0, 1, 3, 10, 30, 100, 300, and 1000 nM 
paclitaxel and cultured for 48 h.  Then the cells were counted with a hemocytometer.  The 
data represent mean of triplicate experiments and the bars show SD.  The data were 
described in Table 4.  
 
